You are here

Vaccines

Primary tabs

Information on vaccines to counter Ebola and other diseases

The Mission of this group is to follow the development of vaccines and other medications to counter Ebola and other diseases.

Members

Kathy Gilbeaux mdmcdonald MDMcDonald_me_com mike kraft

Email address for group

vaccines_global@m.resiliencesystem.org

Native Americans take steps to vaccinate and reduce COVID-19 spread

...While minority communities across the United States have struggled to trust the vaccine, the opposite is true for the Eastern Band of Cherokee Indians, a Native American tribe of 16,000 in western North Carolina, and other tribes across the country, which were also quick to adopt coronavirus prevention measures.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Grocery workers feeling left out of vaccinations

As panicked Americans cleared supermarkets of toilet paper and food last spring, grocery employees gained recognition as among the most indispensable of the pandemic’s front-line workers.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

WHO listed two versions of the AstraZeneca/Oxford COVID-19 vaccine for emergency use

WHO listed two versions of the AstraZeneca/Oxford COVID-19 vaccine for emergency use, giving the green light for these vaccines to be rolled out globally through COVAX. The vaccines are produced by AstraZeneca-SKBio (Republic of Korea) and the Serum Institute of India.

Problem, Solution, SitRep, or ?: 

ANALYSIS" The need for global access to COVID-19 vaccines: production, affordability, allocation, and deployment

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00306-8/fulltext

The COVID-19 pandemic is unlikely to end until there is global roll-out of vaccines that protect against severe disease and preferably drive herd immunity. Regulators in numerous countries have authorised or approved COVID-19 vaccines for human use, with more expected to be licensed in 2021. Yet having licensed vaccines is not enough to achieve global control of COVID-19: they also need to be produced at scale, priced affordably, allocated globally so that they are available where needed, and widely deployed in local communities.

In this Health Policy paper, we review potential challenges to success in each of these dimensions and discuss policy implications. To guide our review, we developed a dashboard to highlight key characteristics of 26 leading vaccine candidates, including efficacy levels, dosing regimens, storage requirements, prices, production capacities in 2021, and stocks reserved for low-income and middle-income countries. We use a traffic-light system to signal the potential contributions of each candidate to achieving global vaccine immunity, highlighting important trade-offs that policy makers need to consider when developing and implementing vaccination programmes. ...

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Pages

howdy folks
Page loaded in 1.014 seconds.